Nexium Prescribers Should Be “Embarrassed,” CMS’ Scully Tells AMA
Executive Summary
There is no medical justification for prescribers to choose AstraZeneca's Nexium (esomeprazole) over Prilosec (omeprazole), Centers for Medicare & Medicaid Services Administrator Thomas Scully declared during the American Medical Association advocacy conference March 5 in Washington, D.C
You may also be interested in...
“Lifestyle” Drug Coverage Will Be Federal Policy Issue Under Medicare Rx
The debate over coverage of "lifestyle" drugs is likely to intensify as a federal policy issue once the Medicare prescription drug benefit takes effect in 2006
“Lifestyle” Drug Coverage Will Be Federal Policy Issue Under Medicare Rx
The debate over coverage of "lifestyle" drugs is likely to intensify as a federal policy issue once the Medicare prescription drug benefit takes effect in 2006
AstraZeneca Sets Two NMEs Per Year As Metric Of R&D Success
AstraZeneca is setting a goal of launching two new molecular entities each year, Exec VP-Global Drug Development Martin Nicklasson, PhD, said Feb. 10 at a drug development summit sponsored by R&D Directions in Phoenix